within Pharmacolibrary.Drugs.ATC.N;

model N05CJ02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.94,
    Cl             = 0.017333333333333333,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.048799999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Lemborexant is a dual orexin receptor antagonist used for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. It is an orally active, prescription hypnotic agent approved for adults by regulatory agencies such as the FDA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult subjects (aged 18â€“88), both male and female, primarily following oral administration in clinical and Phase I studies.</p><h4>References</h4><ol><li>Ishani Landry, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Satish Dayal, Margaret Moline, Larisa Reyderman,Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug-Drug Interaction Study in Healthy Females.,Clinical pharmacology in drug development,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34107159/'>https://pubmed.ncbi.nlm.nih.gov/34107159/</a></li><li>Satish Dayal, Jagadeesh Aluri, Nancy Hall, Gleb Filippov, Margaret Moline, Larisa Reyderman, Ishani Landry,Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.,Pharmacology research & perspectives,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33822479/'>https://pubmed.ncbi.nlm.nih.gov/33822479/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CJ02;
